CG Oncology, Inc. Common stock (CGON) Revenue History
Annual and quarterly revenue from 2021 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CGON Revenue Growth
Revenue Breakdown (FY 2025)
CGON's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
CGON Revenue Analysis (2021–2025)
As of May 8, 2026, CG Oncology, Inc. Common stock (CGON) generated trailing twelve-month (TTM) revenue of $4.0 million, reflecting explosive growth of +409.2% year-over-year. The most recent quarter (Q4 2025) recorded $2.3 million in revenue, up 39.4% sequentially.
Looking at the longer-term picture, CGON's historical revenue data shows a 3-year CAGR of +176.6%. The company achieved its highest annual revenue of $10.4 million in 2021.
Revenue diversification analysis shows CGON's business is primarily driven by License And Collaboration Revenue (100%). With over half of revenue concentrated in License And Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including GRVY (+1.7% YoY), TGTX (+81.3% YoY), and JANX (+68.9% YoY), CGON has outperformed the peer group in terms of revenue growth. Compare CGON vs GRVY →
CGON Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CGONCurrent | $4M | +409.2% | - | -4722.1% | |
 GRVY | $568.1B | +1.7% | +7.0% | 14.1% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% | |
 JANX | $10M | +68.9% | - | -1576.7% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% |
CGON Historical Revenue Data (2021–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $4.0M | +254.7% | $-607,000 | -15.0% | $-190,774,000 | -4722.1% |
| 2024 | $1.1M | +458.3% | $1.1M | 100.0% | $-114,666,000 | -10067.3% |
| 2023 | $204K | +6.8% | $204K | 100.0% | $-55,449,000 | -27180.9% |
| 2022 | $191K | -98.2% | $176K | 92.1% | $-35,246,000 | -18453.4% |
| 2021 | $10.4M | - | $10.3M | 99.9% | $-12,606,000 | -121.7% |
See CGON's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CGON Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CGON vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCGON — Frequently Asked Questions
Quick answers to the most common questions about buying CGON stock.
Is CGON's revenue growth accelerating or slowing?
CGON revenue is accelerating at +409.2% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $4M. Growth momentum has increased versus prior periods.
What is CGON's long-term revenue growth rate?
CG Oncology, Inc. Common stock's 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +409.2% is above this long-term average.
How is CGON's revenue distributed by segment?
CGON reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2021-2025 are available for download. Segment mix reveals concentration and diversification trends.